Search

Your search keyword '"Choe, Jun-Ho"' showing total 446 results
Start Over Author "Choe, Jun-Ho"
446 results on '"Choe, Jun-Ho"'

5. Feasibility of active surveillance in patients with clinically T1b papillary thyroid carcinoma ≤1.5 cm in preoperative ultrasonography: MASTER study

Author

Ju, Sang-Hyeon, primary, Ji, Yong Bae, additional, Song, Minchul, additional, Lim, Joung Youl, additional, Heo, Da Beom, additional, Kim, Min-Gyu, additional, Chang, Jae Won, additional, Won, Ho-Ryun, additional, Kang, Yea Eun, additional, Ku, Eu Jeong, additional, Kim, Mijin, additional, Lee, Eun Kyung, additional, Choi, June Young, additional, Yu, Hyeong Won, additional, Park, Young Joo, additional, Choe, Jun-Ho, additional, Koo, Bon Seok, additional, and _, _, additional

Published
2024
Full Text
View/download PDF

27. Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease

Author

Kim, Jinyoung, Choi, Min Sun, Park, Jun, Park, Hyunju, Jang, Hye Won, Choe, Jun-Ho, Kim, Jung-Han, Kim, Jee Soo, Cho, Young Seok, Choi, Joon Young, Kim, Tae Hyuk, Chung, Jae Hoon, and Kim, Sun Wook

Subjects
Adult, Male, Graves'disease, Goiter, thyrotropin receptor antibody, Drug Resistance, Receptors, Thyrotropin, Kaplan-Meier Estimate, Middle Aged, Thyroid Function Tests, radioactive iodine therapy, Graves Disease, total thyroidectomy, Iodine Radioisotopes, Treatment Outcome, hemic and lymphatic diseases, Thyroidectomy, Humans, thyrotropin-binding inhibitory immunoglobulins, Female, Immunology, Autoimmunity, and Graves' Ophthalmopathy, Aged, Immunoglobulins, Thyroid-Stimulating, Retrospective Studies
Abstract

Background: The actions of thyrotropin-binding inhibitory immunoglobulins (TBIIs) against thyrotropin receptors in thyroid follicular cells have been studied as important etiological factors in Graves' disease (GD). The purpose of this study was to investigate changes in the TBII levels of patients undergoing total thyroidectomy (TTx) or radioactive iodine (RAI) therapy for GD refractory to antithyroid drugs (ATDs). Methods: We enrolled patients who underwent TTx or RAI for GD with previous ATD use between January 2011 and December 2017 at the Samsung Medical Center in Seoul, Korea. Thorough retrospective reviews of medical records were performed in 130 patients. Results: Patients with goiter, ophthalmopathy, high levels of TBIIs, and high doses of ATDs received TTx. Elderly patients with arrhythmia received RAI. We observed that TBII levels continued to decrease after TTx. On the contrary, TBIIs initially increased for 138 days (estimated median time) and then decreased slowly after RAI. A faster decline in TBII levels was observed in the TTx group than in the RAI group (p 4.5 IU/L) were present in 70 (82%) at 6 months, 57 (67%) at 1 year, and 3 (3%) at 2 years. In the TTx group, rapid decreases in TBII levels were observed in younger patients and those with lower baseline TBII levels. In the RAI group, smaller thyroid volume was correlated with more rapid decrease in TBII levels. Conclusions: The changes in TBII levels following TTx or RAI were different in patients with refractory GD. When deciding on TTx or RAI, this difference should be considered with patient age, severity of hyperthyroidism, goiter, ophthalmopathy, and future pregnancy plans (for young female patients).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results